EGFR and glioblastoma: Although there is a paucity of information on how TERT mutations could impact tumor recurrence, the presence of TERT promoter mutations is associated with other biomarkers relevant to tumor cell survival/progression such as EGFR amplifications (a dominant mutation in newly diagnosed glioblastoma prior to treatment) and PTEN mutations (dominant in recurrent glioblastoma) [54,55,56].